Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bristol-Myers Squibb Company (BMY)
USD59.34
+1.76 (+3.06%)
US NYSE S&P 500
Healthcare Drug Manufacturers - General
Address
Route 206 & Province Line Road 8543
Princeton, NJ, US
Princeton, NJ, US
CEO
Christopher S. Boerner
Website
bms.com
IPO
1972-06-01
CIK 14272 ISIN US1101221083
Also trades on
Deutsche Börse · BRM.DE (EUR)
London Stock Exchange · 0R1F.L (USD)
New York Stock Exchange · BMY (USD)
Other OTC · BMYMP (USD)
Swiss Exchange · BMY.SW (USD)
Description
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
News Sentiment (7d)
3 articles
- Start Investing At 60 And Retire On Dividends Forever Seeking Alpha
- Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment Benzinga
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma Business Wire
Market Cap & Enterprise Value
Merger & Acquisition History
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1957-03-04 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD59.34
+1.76 (+3.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.24
Float Shares
2.04B
Free Float %
99.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.87% | -1.36% | -5.03% | -7.00% | +13.43% | +3.21% | +15.55% | -18.20% | -13.73% | -21.90% | +2,642.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (41 ratings, all time)
Hold
Price Targets & DCF
Current price
59.34
Low
40.00
-32.6%
Consensus
62.00
+4.5%
Median
60.00
+1.1%
High
75.00
+26.4%
DCF (Unlevered)
281.86
+375.0%
DCF (Levered)
311.89
+425.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
34% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 6 | 0 |
| Hold | 18 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 5 |
66.80
+12.6%
|
| Last Year | 19 |
60.68
+2.3%
|
| All Time | 46 |
64.87
+9.3%
|
Quality scores
Altman Z-Score
2.41
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%-0.2% Q1'26: +2.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+178.2% ★ Q1'26: +9.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+18.7% ★ Q1'26: +6.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+22.2% ★ Q1'26: +28.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+14.7% ★ Q1'26: +20.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.7% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×3.24× Q1'26: 3.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 20 Rev. Ana. 17 EPS Ana. |
Dec 2027 21 Rev. Ana. 17 EPS Ana. |
Dec 2028 23 Rev. Ana. 9 EPS Ana. |
Dec 2029 11 Rev. Ana. 3 EPS Ana. |
Dec 2030 11 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
21.24B
est: 20.66B (+2.8%)
|
17.62B
est: 17.27B (+2.0%)
|
16.39B
est: 15.51B (+5.6%)
|
15.88B
est: 14.58B (+8.9%)
|
16.56B
est: 16.42B (+0.9%)
|
19.43B
est: 19.30B (+0.7%)
|
20.78B
est: 20.67B (+0.5%)
|
22.56B
est: 22.57B (0.0%)
|
26.15B
est: 25.33B (+3.2%)
|
42.52B
est: 42.20B (+0.8%)
|
46.39B
est: 46.46B (-0.2%)
|
46.16B
est: 45.92B (+0.5%)
|
45.01B
est: 46.51B (-3.2%)
|
48.30B
est: 47.51B (+1.7%)
|
48.19B
est: 47.99B (+0.4%)
|
47.27B
46.71B – 47.50B
-1.5% YoY
|
46.27B
45.07B – 47.53B
-2.1% YoY
|
40.97B
40.87B – 41.06B
-11.5% YoY
|
37.38B
36.42B – 38.01B
-8.7% YoY
|
36.66B
35.71B – 37.27B
-1.9% YoY
|
| EBITDA |
7.75B
est: 6.16B (+25.9%)
|
3.20B
est: 2.53B (+26.4%)
|
3.85B
est: 3.59B (+7.5%)
|
3.05B
est: 2.80B (+9.1%)
|
2.64B
est: 1.86B (+42.1%)
|
6.46B
est: 5.88B (+9.9%)
|
6.12B
est: 5.87B (+4.2%)
|
6.79B
est: 5.79B (+17.3%)
|
7.38B
est: 6.43B (+14.8%)
|
4.93B
est: 3.87B (+27.5%)
|
20.12B
est: 19.63B (+2.5%)
|
19.22B
est: 18.64B (+3.1%)
|
19.37B
est: 15.33B (+26.3%)
|
3.17B
est: 15.66B (-79.8%)
|
14.55B
est: 15.82B (-8.0%)
|
15.58B
15.40B – 15.66B
-1.5% YoY
|
15.25B
14.85B – 15.66B
-2.1% YoY
|
13.50B
13.47B – 13.53B
-11.5% YoY
|
12.32B
12.00B – 12.53B
-8.7% YoY
|
12.08B
11.77B – 12.28B
-1.9% YoY
|
| EBIT |
7.13B
est: 6.43B (+10.8%)
|
2.52B
est: 4.04B (-37.5%)
|
3.09B
est: 2.73B (+13.0%)
|
2.58B
est: 1.59B (+62.8%)
|
2.26B
est: 1.21B (+86.1%)
|
6.08B
est: 4.17B (+46.0%)
|
5.33B
est: 3.30B (+61.6%)
|
6.15B
est: 4.40B (+39.9%)
|
5.63B
est: 5.32B (+5.8%)
|
-5.45B
est: 1.88B (-390.1%)
|
9.43B
est: 7.31B (+29.1%)
|
8.95B
est: 11.04B (-18.9%)
|
9.61B
est: 6.50B (+47.7%)
|
-6.43B
est: 6.64B (-196.8%)
|
10.68B
est: 6.71B (+59.2%)
|
6.61B
6.53B – 6.64B
-1.5% YoY
|
6.47B
6.30B – 6.65B
-2.1% YoY
|
5.73B
5.71B – 5.74B
-11.5% YoY
|
5.23B
5.09B – 5.31B
-8.7% YoY
|
5.13B
4.99B – 5.21B
-1.9% YoY
|
| Net Income |
3.71B
est: 3.58B (+3.6%)
|
1.96B
est: 1.84B (+6.5%)
|
2.56B
est: 2.40B (+6.9%)
|
2.00B
est: 1.86B (+8.0%)
|
1.57B
est: 1.14B (+36.8%)
|
4.46B
est: 4.09B (+9.0%)
|
1.01B
est: 850.99M (+18.3%)
|
4.92B
est: 4.20B (+17.0%)
|
3.44B
est: 3.56B (-3.3%)
|
-9.00B
est: -8.69B (-3.5%)
|
6.99B
est: 6.97B (+0.3%)
|
6.33B
est: 6.77B (-6.6%)
|
8.03B
est: -6.54B (+222.7%)
|
-8.95B
est: 1.93B (-563.9%)
|
7.05B
est: 12.70B (-44.5%)
|
12.89B
12.41B – 13.37B
+1.5% YoY
|
12.42B
11.27B – 13.57B
-3.6% YoY
|
8.85B
8.19B – 13.02B
-28.7% YoY
|
9.97B
9.63B – 10.18B
+12.6% YoY
|
9.91B
9.58B – 10.12B
-0.6% YoY
|
| SGA |
5.13B
est: 5.02B (+2.2%)
|
5.02B
est: 5.04B (-0.6%)
|
4.94B
est: 4.80B (+2.9%)
|
4.82B
est: 5.16B (-6.6%)
|
4.83B
est: 3.40B (+42.0%)
|
4.91B
est: 4.69B (+4.8%)
|
4.75B
est: 4.71B (+0.9%)
|
4.55B
est: 3.91B (+16.5%)
|
4.86B
est: 3.98B (+22.1%)
|
7.65B
est: 7.00B (+9.2%)
|
7.69B
est: 7.60B (+1.2%)
|
7.81B
est: 7.86B (-0.7%)
|
7.68B
est: 7.61B (+0.8%)
|
7.87B
est: 7.78B (+1.1%)
|
7.24B
est: 7.86B (-7.8%)
|
7.74B
7.65B – 7.78B
-1.5% YoY
|
7.58B
7.38B – 7.78B
-2.1% YoY
|
6.71B
6.69B – 6.72B
-11.5% YoY
|
6.12B
5.96B – 6.22B
-8.7% YoY
|
6.00B
5.85B – 6.10B
-1.9% YoY
|
| EPS |
2.18
est: 2.14 (+1.9%)
|
1.17
est: 1.92 (-39.1%)
|
1.56
est: 1.62 (-3.7%)
|
1.21
est: 1.55 (-21.9%)
|
0.97
est: 1.91 (-49.1%)
|
2.67
est: 2.86 (-6.6%)
|
0.61
est: 3.00 (-79.7%)
|
3.03
est: 3.87 (-21.8%)
|
2.02
est: 4.65 (-56.6%)
|
-3.98
est: 6.40 (-162.2%)
|
3.15
est: 7.47 (-57.8%)
|
2.97
est: 7.39 (-59.8%)
|
3.88
est: -3.22 (+220.6%)
|
-4.41
est: 0.92 (-581.8%)
|
3.46
est: 6.11 (-43.4%)
|
6.31
6.08 – 6.55
+3.2% YoY
|
6.15
5.52 – 6.65
-2.5% YoY
|
5.39
4.01 – 6.38
-12.4% YoY
|
4.88
4.72 – 4.99
-9.4% YoY
|
4.86
4.69 – 4.96
-0.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
12.06B
OE per share TTM
5.92
Owner's Yield
10.60%
Maintenance CapEx ratio
11.05%
Maint CapEx / Avg PPE
17.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1,052
Total invested
7.32B
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group - 23-1945930 | 199.83M | 9.00% | — | 3.54M | 190.66M | 9.17M | IA | — | 2022-02-09 | ↗ |
| 2 | (1) BlackRock, Inc. | 169.23M | 7.60% | 147.72M | — | 169.23M | — | HC | Delaware | 2022-02-01 | ↗ |
| 3 | Wellington Management Company LLP | 113.64M | 6.95% | — | 23.96M | — | — | IA | Massachusetts | 2019-05-10 | ↗ |
| 4 | Wellington Group Holdings LLP | 83.47M | 3.57% | — | 79.45M | — | — | HC | Delaware | 2020-01-28 | ↗ |
| 5 | Wellington Investment Advisors Holdings LLP | 83.47M | 3.57% | — | 79.45M | — | — | HC | Delaware | 2020-01-28 | ↗ |
| 6 | Wellington Management Group LLP | 83.47M | 3.57% | — | 79.45M | — | — | HC | Massachusetts | 2020-01-28 | ↗ |
| 7 | BRISTOL-MYERS SQUIBB COMPANY 22-0790350 | 11.95M | 9.90% | — | 11.95M | — | 11.95M | CO | Delaware, U.S.A. | 2021-07-26 | ↗ |
| 8 | CELGENE CORPORATION 22-2711928 | 11.95M | 9.90% | — | 11.95M | — | 11.95M | CO | Delaware, U.S.A. | 2021-07-26 | ↗ |
| 9 | Bristol-Myers Squibb Company | 759.1K | 6.23% | 759.1K | — | 759.1K | — | CO | Delaware | 2024-11-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1,052
-1,464 vs prev Q
New positions
99
Closed positions
1,489
Increased
551
Reduced
358
Put/Call ratio
1.76
Calls held
270.2K
Puts held
476.8K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 198.73M +2.7M (+1.4%) | 10.72B +1.9B (+21.3%) | 9.74% +0.106 pp | 0.16% +0.023 pp | USD61.23 -11.9% | 84 qtrs — |
| 2 | BLACKROCK, INC. | 176.83M +1.3M (+0.7%) | 9.54B +1.6B (+20.5%) | 8.66% +0.039 pp | 0.16% +0.023 pp | USD51.49 +4.8% | 6 qtrs — |
| 3 | STATE STREET CORP | 97.98M +1.4M (+1.4%) | 5.29B +928.6M (+21.3%) | 4.80% +0.054 pp | 0.18% +0.026 pp | USD53.18 +1.4% | 51 qtrs — |
| 4 | JPMORGAN CHASE & CO | 75.37M -10.8M (-12.5%) | 4.07B +178.6M (+4.6%) | 3.70% -0.533 pp | 0.26% +0.022 pp | USD58.73 -8.2% | 51 qtrs — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 71.32M -1.7M (-2.4%) | 3.85B +553.0M (+16.8%) | 3.49% -0.095 pp | 0.60% +0.072 pp | USD51.00 +5.8% | 100 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 52.64M +6.1M (+13.1%) | 2.84B +740.8M (+35.3%) | 2.58% +0.291 pp | 0.18% +0.041 pp | USD52.30 +3.1% | 78 qtrs — |
| 7 | NORGES BANK | 36.10M +36.1M (+100.0%) | 1.95B +1.9B (+100.0%) | 1.77% +1.769 pp | 0.21% +0.208 pp | USD53.94 +0.0% | 1 qtrs NEW |
| 8 | MORGAN STANLEY | 28.35M +480.9K (+1.7%) | 1.53B +272.3M (+21.7%) | 1.39% +0.020 pp | 0.09% +0.015 pp | USD62.47 -13.7% | 51 qtrs — |
| 9 | AMERIPRISE FINANCIAL INC | 28.06M -4.4M (-13.6%) | 1.51B +49.0M (+3.3%) | 1.37% -0.221 pp | 0.34% +0.006 pp | USD53.32 +1.2% | 55 qtrs — |
| 10 | AQR CAPITAL MANAGEMENT LLC | 25.80M +16.3M (+172.6%) | 1.39B +965.1M (+226.4%) | 1.26% +0.799 pp | 0.73% +0.457 pp | USD53.85 +0.2% | 92 qtrs — |
| 11 | PRIMECAP MANAGEMENT CO/CA/ | 24.88M +2.8M (+12.6%) | 1.34B +345.3M (+34.7%) | 1.22% +0.133 pp | 1.02% +0.253 pp | USD57.23 -5.7% | 36 qtrs — |
| 12 | NORTHERN TRUST CORP | 24.60M -26.5K (-0.1%) | 1.33B +216.2M (+19.5%) | 1.21% -0.005 pp | 0.17% +0.027 pp | USD53.28 +1.2% | 51 qtrs — |
| 13 | BANK OF NEW YORK MELLON CORP | 24.50M +7.8M (+47.0%) | 1.32B +570.0M (+75.9%) | 1.20% +0.382 pp | 0.24% +0.089 pp | USD56.64 -4.8% | 66 qtrs — |
| 14 | UBS ASSET MANAGEMENT AMERICAS INC | 21.44M -351.4K (-1.6%) | 1.16B +173.7M (+17.7%) | 1.05% -0.020 pp | 0.24% +0.031 pp | USD51.88 +4.0% | 90 qtrs — |
| 15 | CAPITAL INTERNATIONAL INVESTORS | 20.99M -11.4M (-35.2%) | 1.13B -328.0M (-22.5%) | 1.03% -0.563 pp | 0.18% -0.058 pp | USD66.32 -18.7% | 16 qtrs — |
| 16 | INDEPENDENT FRANCHISE PARTNERS LLP | 20.83M +204.8K (+1.0%) | 1.12B +193.4M (+20.8%) | 1.02% +0.007 pp | 7.14% +1.014 pp | USD55.50 -2.8% | 26 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 18.34M +758.0K (+4.3%) | 989.42M +196.3M (+24.8%) | 0.90% +0.037 pp | 0.12% +0.024 pp | USD58.10 -7.2% | 73 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 18.24M +98.6K (+0.5%) | 984.07M +166.0M (+20.3%) | 0.89% +0.002 pp | 0.21% +0.031 pp | USD55.82 -3.4% | 51 qtrs — |
| 19 | PZENA INVESTMENT MANAGEMENT LLC | 17.94M +3.0M (+20.4%) | 967.87M +295.8M (+44.0%) | 0.88% +0.149 pp | 2.90% +0.726 pp | USD54.96 -1.9% | 26 qtrs — |
| 20 | LEGAL & GENERAL GROUP PLC | 17.37M +290.3K (+1.7%) | 936.72M +166.6M (+21.6%) | 0.85% +0.012 pp | 0.21% +0.035 pp | USD51.54 +4.7% | 75 qtrs — |
| 21 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 17.19M +2.4M (+15.9%) | 927.26M +258.2M (+38.6%) | 0.84% +0.113 pp | 0.54% +0.121 pp | USD48.85 +10.4% | 19 qtrs — |
| 22 | INVESCO LTD. | 16.83M -793.6K (-4.5%) | 907.94M +113.0M (+14.2%) | 0.82% -0.041 pp | 0.14% +0.014 pp | USD53.89 +0.1% | 57 qtrs — |
| 23 | BANK OF AMERICA CORP /DE/ | 15.06M -1.8M (-10.8%) | 812.30M +50.6M (+6.6%) | 0.74% -0.092 pp | 0.06% +0.007 pp | USD64.77 -16.7% | 52 qtrs — |
| 24 | ROYAL BANK OF CANADA | 12.64M -200.8K (-1.6%) | 681.99M +102.7M (+17.7%) | 0.62% -0.012 pp | 0.11% +0.016 pp | USD55.67 -3.1% | 51 qtrs — |
| 25 | SCHRODER INVESTMENT MANAGEMENT GROUP | 12.55M +385.4K (+3.2%) | 680.57M +131.8M (+24.0%) | 0.62% +0.017 pp | 0.52% +0.092 pp | USD52.14 +3.5% | 51 qtrs — |
| 26 | MARSHALL WACE, LLP | 10.84M +9.3M (+607.1%) | 584.94M +515.8M (+745.7%) | 0.53% +0.456 pp | 0.53% +0.462 pp | USD52.69 +2.4% | 3 qtrs — |
| 27 | VAN ECK ASSOCIATES CORP | 10.55M +693.8K (+7.0%) | 569.27M +124.6M (+28.0%) | 0.52% +0.033 pp | 0.47% +0.057 pp | USD47.94 +12.5% | 57 qtrs — |
| 28 | FMR LLC | 10.25M -48.9K (-0.5%) | 552.90M +88.4M (+19.0%) | 0.50% -0.004 pp | 0.03% +0.004 pp | USD58.38 -7.6% | 70 qtrs — |
| 29 | DEUTSCHE BANK AG\ | 8.80M +226.1K (+2.6%) | 474.44M +88.0M (+22.8%) | 0.43% +0.011 pp | 0.15% +0.025 pp | USD61.00 -11.6% | 50 qtrs — |
| 30 | LSV ASSET MANAGEMENT | 8.65M +383.3K (+4.6%) | 466.73M +93.8M (+25.1%) | 0.42% +0.018 pp | 1.02% +0.194 pp | USD58.43 -7.7% | 31 qtrs — |
| 31 | FRANKLIN RESOURCES INC | 8.55M -151.0K (-1.7%) | 461.25M +68.8M (+17.5%) | 0.42% -0.009 pp | 0.11% +0.015 pp | USD50.76 +6.3% | 51 qtrs — |
| 32 | PACER ADVISORS, INC. | 8.38M -925.6K (-9.9%) | 451.97M +32.3M (+7.7%) | 0.41% -0.046 pp | 1.15% +0.098 pp | USD54.90 -1.7% | 41 qtrs — |
| 33 | MAN GROUP PLC | 8.32M -910.6K (-9.9%) | 448.65M +32.5M (+7.8%) | 0.41% -0.046 pp | 0.76% +0.039 pp | USD46.38 +16.3% | 32 qtrs — |
| 34 | TWO SIGMA ADVISERS, LP | 8.27M +3.5M (+75.2%) | 446.09M +233.2M (+109.5%) | 0.41% +0.173 pp | 0.87% +0.441 pp | USD49.74 +8.4% | 38 qtrs — |
| 35 | VICTORY CAPITAL MANAGEMENT INC | 8.20M +4.1M (+102.1%) | 442.55M +259.5M (+141.7%) | 0.40% +0.203 pp | 0.25% +0.143 pp | USD55.09 -2.1% | 45 qtrs — |
| 36 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 7.70M -100.0K (-1.3%) | 415.11M +63.5M (+18.1%) | 0.38% -0.006 pp | 0.05% +0.008 pp | USD48.35 +11.6% | 51 qtrs — |
| 37 | BARCLAYS PLC | 7.32M +486.4K (+7.1%) | 394.75M +41.3M (+11.7%) | 0.36% +0.023 pp | 0.09% +0.004 pp | USD57.54 -6.3% | 51 qtrs — |
| 38 | M&G PLC | 7.14M +250.3K (+3.6%) | 385.32M +75.5M (+24.4%) | 0.35% +0.011 pp | 1.98% +0.332 pp | USD50.09 +7.7% | 8 qtrs — |
| 39 | DODGE & COX | 7.08M -345.6K (-4.7%) | 381.80M +47.0M (+14.0%) | 0.35% -0.018 pp | 0.21% +0.025 pp | USD55.22 -2.3% | 108 qtrs — |
| 40 | WELLINGTON MANAGEMENT GROUP LLP | 6.92M -10.2M (-59.7%) | 373.35M -400.4M (-51.7%) | 0.34% -0.504 pp | 0.07% -0.070 pp | USD58.72 -8.1% | 81 qtrs — |
| 41 | BNP PARIBAS ARBITRAGE, SNC | 6.89M +2.4M (+52.2%) | 371.82M +167.6M (+82.1%) | 0.34% +0.115 pp | 0.17% +0.059 pp | USD57.04 -5.4% | 51 qtrs — |
| 42 | PRICE T ROWE ASSOCIATES INC /MD/ | 6.88M -839.6K (-10.9%) | 371.08M +22.9M (+6.6%) | 0.34% -0.042 pp | 0.04% +0.003 pp | USD53.70 +0.4% | 75 qtrs — |
| 43 | ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. | 6.70M -105.8K (-1.6%) | 361.66M +54.5M (+17.7%) | 0.33% -0.005 pp | 0.52% +0.070 pp | USD54.80 -1.6% | 74 qtrs — |
| 44 | FIL LTD | 6.49M +566.2K (+9.6%) | 350.19M +82.9M (+31.0%) | 0.32% +0.027 pp | 0.26% +0.052 pp | USD55.03 -2.0% | 48 qtrs — |
| 45 | HSBC HOLDINGS PLC | 6.42M +1.6M (+33.8%) | 347.43M +130.6M (+60.3%) | 0.32% +0.080 pp | 0.18% +0.058 pp | USD59.35 -9.1% | 56 qtrs — |
| 46 | UBS GROUP AG | 6.15M -4.5M (-42.3%) | 331.79M -148.8M (-31.0%) | 0.30% -0.222 pp | 0.05% -0.022 pp | USD55.01 -1.9% | 45 qtrs — |
| 47 | AMUNDI | 6.03M +57.0K (+1.0%) | 325.34M +55.7M (+20.6%) | 0.30% +0.002 pp | 0.09% +0.002 pp | USD58.24 -7.4% | 19 qtrs — |
| 48 | ACADIAN ASSET MANAGEMENT LLC | 5.97M +2.9M (+94.1%) | 322.18M +183.4M (+132.1%) | 0.29% +0.141 pp | 0.53% +0.287 pp | USD50.23 +7.4% | 50 qtrs — |
| 49 | WELLS FARGO & COMPANY/MN | 5.94M +398.6K (+7.2%) | 320.36M +70.5M (+28.2%) | 0.29% +0.019 pp | 0.06% +0.011 pp | USD57.09 -5.5% | 57 qtrs — |
| 50 | SWISS NATIONAL BANK | 5.58M -288.6K (-4.9%) | 300.86M +36.3M (+13.7%) | 0.27% -0.015 pp | 0.18% +0.026 pp | USD58.92 -8.5% | 51 qtrs — |
| 51 | NATIONAL PENSION SERVICE | 5.53M +426.7K (+8.4%) | 298.46M +68.2M (+29.6%) | 0.27% +0.020 pp | 0.22% +0.042 pp | USD58.32 -7.5% | 46 qtrs — |
| 52 | NUVEEN, LLC | 5.53M -473.5K (-7.9%) | 298.09M +27.5M (+10.2%) | 0.27% -0.024 pp | 0.08% +0.007 pp | USD60.99 -11.6% | 4 qtrs — |
| 53 | ALLIANZ ASSET MANAGEMENT GMBH | 5.50M +298.4K (+5.7%) | 296.42M +62.0M (+26.5%) | 0.27% +0.014 pp | 0.30% +0.038 pp | USD54.48 -1.0% | 51 qtrs — |
| 54 | FIRST TRUST ADVISORS LP | 5.29M -337.7K (-6.0%) | 285.40M +31.5M (+12.4%) | 0.26% -0.017 pp | 0.21% +0.018 pp | USD48.77 +10.6% | 51 qtrs — |
| 55 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 5.21M -54.8K (-1.0%) | 280.76M +43.5M (+18.4%) | 0.26% -0.003 pp | 0.16% +0.028 pp | USD51.63 +4.5% | 59 qtrs — |
| 56 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 5.11M -533.8K (-9.5%) | 275.75M +21.1M (+8.3%) | 0.25% -0.027 pp | 0.16% +0.005 pp | USD57.42 -6.1% | 58 qtrs — |
| 57 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 4.76M +233.9K (+5.2%) | 254.40M +50.3M (+24.7%) | 0.23% +0.011 pp | 0.17% +0.026 pp | USD56.06 -3.8% | 58 qtrs — |
| 58 | TWO SIGMA INVESTMENTS, LP | 4.66M -791.3K (-14.5%) | 251.47M +5.5M (+2.2%) | 0.23% -0.040 pp | 0.35% -0.011 pp | USD46.00 +17.3% | 42 qtrs — |
| 59 | CANADA PENSION PLAN INVESTMENT BOARD | 4.52M +2.1M (+83.9%) | 243.72M +132.9M (+119.9%) | 0.22% +0.101 pp | 0.16% +0.085 pp | USD58.10 -7.2% | 52 qtrs — |
| 60 | RUSSELL INVESTMENTS GROUP, LTD. | 4.49M +820.8K (+22.4%) | 242.47M +77.4M (+46.9%) | 0.22% +0.040 pp | 0.26% +0.077 pp | USD55.12 -2.1% | 37 qtrs — |
| 61 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 4.47M +2.5M (+121.9%) | 240.97M +150.7M (+166.9%) | 0.22% +0.120 pp | 0.28% +0.043 pp | USD56.22 -4.1% | 51 qtrs — |
| 62 | CITADEL ADVISORS LLC | 4.00M +163.3K (+4.3%) | 215.63M +42.7M (+24.7%) | 0.20% +0.007 pp | 0.03% +0.006 pp | USD49.65 +8.6% | 38 qtrs — |
| 63 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 4.00M +275.5K (+7.4%) | 215.55M +47.8M (+28.5%) | 0.20% +0.013 pp | 0.86% +0.191 pp | USD48.58 +11.0% | 41 qtrs — |
| 64 | RAYMOND JAMES FINANCIAL INC | 3.98M +732.1K (+22.6%) | 214.60M +68.2M (+46.6%) | 0.19% +0.035 pp | 0.07% +0.020 pp | USD56.70 -4.9% | 5 qtrs — |
| 65 | KBC GROUP NV | 3.97M -102.8K (-2.5%) | 213.99M +30.4M (+16.6%) | 0.19% -0.005 pp | 0.49% +0.048 pp | USD54.01 -0.1% | 69 qtrs — |
| 66 | LOS ANGELES CAPITAL MANAGEMENT LLC | 4.32M +1.1M (+34.1%) | 196.87M +51.7M (+35.7%) | 0.21% +0.053 pp | 0.67% +0.179 pp | USD50.20 +7.5% | 58 qtrs — |
| 67 | RHUMBLINE ADVISERS | 3.58M -84.8K (-2.3%) | 193.10M +27.8M (+16.8%) | 0.18% -0.005 pp | 0.16% +0.023 pp | USD54.52 -1.1% | 51 qtrs — |
| 68 | PNC FINANCIAL SERVICES GROUP, INC. | 3.43M -225.9K (-6.2%) | 185.20M +20.2M (+12.2%) | 0.17% -0.012 pp | 0.10% +0.001 pp | USD49.58 +8.8% | 51 qtrs — |
| 69 | DEKABANK DEUTSCHE GIROZENTRALE | 3.78M +— (+0.0%) | 184.93M +16.1M (+9.5%) | 0.19% -0.001 pp | 0.32% +0.036 pp | USD62.39 -13.5% | 66 qtrs — |
| 70 | ABRDN PLC | 3.40M +216.2K (+6.8%) | 183.23M +40.4M (+28.3%) | 0.17% +0.011 pp | 0.28% +0.058 pp | USD53.42 +1.0% | 34 qtrs — |
| 71 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 3.39M -39.9K (-1.2%) | 183.12M +28.2M (+18.2%) | 0.17% -0.003 pp | 0.18% +0.024 pp | USD53.03 +1.7% | 52 qtrs — |
| 72 | PANAGORA ASSET MANAGEMENT INC | 3.30M +345.0K (+11.7%) | 177.78M +44.7M (+33.6%) | 0.16% +0.017 pp | 0.63% +0.094 pp | USD56.13 -3.9% | 67 qtrs — |
| 73 | NATIONAL BANK OF CANADA /FI/ | 3.08M +1.2M (+62.7%) | 166.33M +80.9M (+94.6%) | 0.15% +0.058 pp | 0.15% +0.066 pp | USD51.89 +4.0% | 17 qtrs — |
| 74 | POINT72 ASSET MANAGEMENT, L.P. | 3.00M +3.0M (+100.0%) | 162.04M +162.0M (+100.0%) | 0.15% +0.147 pp | 0.18% +0.181 pp | USD53.94 +0.0% | 1 qtrs NEW |
| 75 | SWEDBANK AB | 2.98M +5.6K (+0.2%) | 160.71M +26.6M (+19.8%) | 0.15% 0.000 pp | 0.16% +0.020 pp | USD59.42 -9.2% | 20 qtrs — |
| 76 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 2.98M -413.5K (-12.2%) | 160.68M +11.2M (+7.5%) | 0.15% -0.021 pp | 0.28% +0.066 pp | USD54.79 -1.6% | 52 qtrs — |
| 77 | LPL FINANCIAL LLC | 2.85M +134.5K (+4.9%) | 153.92M +31.3M (+25.5%) | 0.14% +0.006 pp | 0.04% +0.006 pp | USD55.63 -3.0% | 51 qtrs — |
| 78 | FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 2.73M +39.7K (+1.5%) | 147.05M +25.9M (+21.4%) | 0.13% +0.002 pp | 0.78% +0.127 pp | USD56.20 -4.0% | 51 qtrs — |
| 79 | ALLIANCEBERNSTEIN L.P. | 2.66M -24.7K (-0.9%) | 143.24M +22.4M (+18.5%) | 0.13% -0.002 pp | 0.05% +0.007 pp | USD58.20 -7.3% | 61 qtrs — |
| 80 | SG AMERICAS SECURITIES, LLC | 2.62M +949.4K (+56.7%) | 141.54M +66.0M (+87.4%) | 0.13% +0.047 pp | 0.18% -0.074 pp | USD51.03 +5.7% | 51 qtrs — |
| 81 | BANK OF MONTREAL /CAN/ | 2.62M +162.9K (+6.6%) | 141.12M +30.5M (+27.5%) | 0.13% +0.008 pp | 0.05% +0.006 pp | USD61.36 -12.1% | 51 qtrs — |
| 82 | QUBE RESEARCH & TECHNOLOGIES LTD | 2.43M -5.7M (-70.0%) | 131.13M -234.8M (-64.2%) | 0.12% -0.280 pp | 0.13% -0.245 pp | USD46.29 +16.5% | 3 qtrs — |
| 83 | CITIGROUP INC | 2.38M -330.5K (-12.2%) | 128.24M +6.1M (+5.0%) | 0.12% -0.017 pp | 0.06% +0.002 pp | USD58.20 -7.3% | 108 qtrs — |
| 84 | RENAISSANCE TECHNOLOGIES LLC | 2.35M -1.3M (-35.8%) | 126.96M -38.5M (-23.2%) | 0.12% -0.065 pp | 0.20% -0.021 pp | USD52.07 +3.6% | 6 qtrs — |
| 85 | NEW YORK STATE COMMON RETIREMENT FUND | 2.35M -20.6K (-0.9%) | 126.67M +19.8M (+18.6%) | 0.12% -0.001 pp | 0.17% +0.031 pp | USD41.64 +29.5% | 103 qtrs — |
| 86 | AUSTRALIANSUPER PTY LTD | 2.33M -26.5K (-1.1%) | 125.93M +19.4M (+18.3%) | 0.11% -0.001 pp | 0.59% +0.096 pp | USD49.34 +9.3% | 26 qtrs — |
| 87 | PRINCIPAL FINANCIAL GROUP INC | 2.32M -37.9K (-1.6%) | 125.24M +18.8M (+17.7%) | 0.11% -0.002 pp | 0.06% +0.010 pp | USD52.21 +3.3% | 81 qtrs — |
| 88 | VIRGINIA RETIREMENT SYSTEMS ET AL | 2.23M +— (+0.0%) | 120.53M +19.8M (+19.6%) | 0.11% 0.000 pp | 0.72% +0.064 pp | USD48.20 +11.9% | 4 qtrs — |
| 89 | ENSIGN PEAK ADVISORS, INC | 2.22M -178.3K (-7.4%) | 119.50M +11.5M (+10.7%) | 0.11% -0.009 pp | 0.21% +0.034 pp | USD62.56 -13.8% | 25 qtrs — |
| 90 | WORLDQUANT MILLENNIUM ADVISORS LLC | 2.17M -991.9K (-31.4%) | 117.03M -25.6M (-17.9%) | 0.11% -0.049 pp | 0.45% -0.162 pp | USD45.20 +19.3% | 31 qtrs — |
| 91 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.12M -96.5K (-4.4%) | 114.10M +14.3M (+14.4%) | 0.10% -0.005 pp | 0.32% +0.004 pp | USD53.54 +0.7% | 57 qtrs — |
| 92 | AMERICAN CENTURY COMPANIES INC | 2.09M -172.8K (-7.6%) | 112.89M +10.7M (+10.5%) | 0.10% -0.009 pp | 0.06% +0.005 pp | USD60.15 -10.3% | 51 qtrs — |
| 93 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 2.08M -201.5K (-8.8%) | 112.25M +9.3M (+9.0%) | 0.10% -0.010 pp | 0.10% +0.007 pp | USD58.63 -8.0% | 37 qtrs — |
| 94 | — | 2.06M +81.0K (+4.1%) | 111.06M +21.9M (+24.5%) | 0.10% +0.004 pp | 0.82% +0.101 pp | USD54.69 -1.4% | 10 qtrs — |
| 95 | SEI INVESTMENTS CO | 2.03M +1.1M (+111.5%) | 109.62M +66.3M (+153.0%) | 0.10% +0.052 pp | 0.11% +0.062 pp | USD55.62 -3.0% | 45 qtrs — |
| 96 | MACQUARIE GROUP LTD | 2.02M +39.9K (+2.0%) | 108.70M +19.6M (+22.0%) | 0.10% +0.002 pp | 0.48% +0.371 pp | USD59.22 -8.9% | 69 qtrs — |
| 97 | STIFEL FINANCIAL CORP | 1.99M +210.4K (+11.8%) | 107.36M +27.1M (+33.7%) | 0.10% +0.010 pp | 0.10% +0.023 pp | USD57.12 -5.6% | 48 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.25
Bearish
Ratio by volume
0.09
Bearish
Buys
1
Sells
4
Shares acquired
3.3K
Shares disposed
35.0K
Cash buys
—
Cash sales
2.00
Net activity
-31,692
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Shanahan Karin | Officer | M-Exempt | A | Common Stock, $0.10 par value | 3,307 | 0.00 | — | 27,580 | D | ↗ |
| 2026-04-01 | Elkins David V | Officer | S-Sale | D | Common Stock, $0.10 par value | 25,519 | 61.60 | 1.57M | 163,729 | D | ↗ |
| 2026-03-31 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 577 | 0.00 | — | 43,904 | D | ↗ |
| 2026-03-31 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 845 | 0.00 | — | 68,728 | D | ↗ |
| 2026-03-31 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 639 | 0.00 | — | 39,964 | D | ↗ |
| 2026-03-31 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 577 | 0.00 | — | 15,557 | D | ↗ |
| 2026-03-31 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 577 | 0.00 | — | 71,435 | D | ↗ |
| 2026-03-10 | Short Bartie Wendy | Officer | M-Exempt | D | Market Share Units | 639 | 0.00 | — | 0 | D | ↗ |
| 2026-03-10 | Shibutani Hiroshi Chris | Officer | A-Award | A | Performance Shares | 11,755 | 0.00 | — | 11,755 | D | ↗ |
| 2026-03-10 | Shanahan Karin | Officer | A-Award | A | Performance Shares | 31,837 | 0.00 | — | 31,837 | D | ↗ |
| 2026-03-10 | Poole Ahn Amanda | Officer | A-Award | A | Performance Shares | 23,020 | 0.00 | — | 23,020 | D | ↗ |
| 2026-03-10 | Plenge Robert M | Officer | M-Exempt | A | Common Stock, $0.10 par value | 14,052 | 0.00 | — | 31,600 | D | ↗ |
| 2026-03-10 | Meyers Gregory Scott | Officer | M-Exempt | D | Performance Shares | 19,760 | 0.00 | — | 0 | D | ↗ |
| 2026-03-10 | Massacesi Cristian | Officer | A-Award | A | Performance Shares | 39,184 | 0.00 | — | 39,184 | D | ↗ |
| 2026-03-10 | Lenkowsky Adam | Officer | J-Other | D | Common Stock, $0.10 par value | 216 | 0.00 | — | 15,015 | D | ↗ |
| 2026-03-10 | Holzer Phil M | Officer | M-Exempt | A | Common Stock, $0.10 par value | 811 | 0.00 | — | 15,778 | D | ↗ |
| 2026-03-10 | Hoch Lynelle | Officer | M-Exempt | D | Performance Shares | 6,304 | 0.00 | — | 0 | D | ↗ |
| 2026-03-10 | Hickey Benjamin | Officer | A-Award | A | Performance Shares | 17,143 | 0.00 | — | 17,143 | D | ↗ |
| 2026-03-10 | Gallman Cari | Officer | M-Exempt | A | Common Stock, $0.10 par value | 912 | 0.00 | — | 11,978 | D | ↗ |
| 2026-03-10 | Elkins David V | Officer | M-Exempt | A | Common Stock, $0.10 par value | 47,424 | 0.00 | — | 222,773 | D | ↗ |
| 2026-03-10 | BOERNER CHRISTOPHER S. | Director / Officer | F-InKind | D | Common Stock, $0.10 par value | 3,073 | 60.13 | 184.8K | 6,984 | D | ↗ |
| 2026-02-01 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 43,327 | D | ↗ |
| 2026-02-01 | Vousden Karen H | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 41,069 | D | ↗ |
| 2026-02-01 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 67,883 | D | ↗ |
| 2026-02-01 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 39,325 | D | ↗ |
| 2026-02-01 | Price Paula A | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 25,498 | D | ↗ |
| 2026-02-01 | Meyers Gregory Scott | Officer | M-Exempt | D | Restricted Stock Units | 2,543 | 0.00 | — | 0 | D | ↗ |
| 2026-02-01 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 14,980 | D | ↗ |
| 2026-02-01 | Hidalgo Medina Manuel | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 22,764 | D | ↗ |
| 2026-02-01 | Hickey Benjamin | Officer | M-Exempt | A | Common Stock, $0.10 par value | 10,079 | 0.00 | — | 18,868 | D | ↗ |
| 2026-02-01 | Haller Julia A | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 37,903 | D | ↗ |
| 2026-02-01 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 19,242 | D | ↗ |
| 2026-02-01 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 3,996 | 0.00 | — | 70,858 | D | ↗ |
| 2025-12-31 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 649 | 0.00 | — | 38,892 | D | ↗ |
| 2025-12-31 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 927 | 0.00 | — | 63,174 | D | ↗ |
| 2025-12-31 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 695 | 0.00 | — | 34,935 | D | ↗ |
| 2025-12-31 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 649 | 0.00 | — | 10,861 | D | ↗ |
| 2025-12-31 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 626 | 0.00 | — | 66,116 | D | ↗ |
| 2025-11-03 | Lenkowsky Adam | Officer | A-Award | A | Restricted Stock Units | 22,568 | 0.00 | — | 22,568 | D | ↗ |
| 2025-11-01 | Shanahan Karin | Officer | M-Exempt | D | Restricted Stock Units | 6,281 | 0.00 | — | 12,562 | D | ↗ |
| 2025-11-01 | Meyers Gregory Scott | Officer | F-InKind | D | Common Stock, $0.10 par value | 2,665 | 46.07 | 122.8K | 19,718 | D | ↗ |
| 2025-11-01 | BOERNER CHRISTOPHER S. | Director / Officer | M-Exempt | D | Market Share Units | 2,964 | 0.00 | — | 5,930 | D | ↗ |
| 2025-10-02 | Gallman Cari | Officer | M-Exempt | A | Common Stock, $0.10 par value | 4,558 | 0.00 | — | 13,398 | D | ↗ |
| 2025-09-30 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 776 | 0.00 | — | 37,735 | D | ↗ |
| 2025-09-30 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 1,109 | 0.00 | — | 61,420 | D | ↗ |
| 2025-09-30 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 831 | 0.00 | — | 33,784 | D | ↗ |
| 2025-09-30 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 776 | 0.00 | — | 10,076 | D | ↗ |
| 2025-09-30 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 748 | 0.00 | — | 64,620 | D | ↗ |
| 2025-09-02 | Elkins David V | Officer | S-Sale | D | Common Stock, $0.10 par value | 56,000 | 47.33 | 2.65M | 167,379 | D | ↗ |
| 2025-09-01 | Short Bartie Wendy | Officer | M-Exempt | A | Common Stock, $0.10 par value | 1,235 | 0.00 | — | 6,301 | D | ↗ |
| 2025-08-02 | Short Bartie Wendy | Officer | M-Exempt | D | Restricted Stock Units | 738 | 0.00 | — | 0 | D | ↗ |
| 2025-08-01 | Massacesi Cristian | Officer | A-Award | A | Restricted Stock Units | 204,691 | 0.00 | — | 204,691 | D | ↗ |
| 2025-08-01 | Gallman Cari | Officer | M-Exempt | A | Common Stock, $0.10 par value | 1,061 | 0.00 | — | 9,383 | D | ↗ |
| 2025-07-01 | Shibutani Hiroshi Chris | Officer | A-Award | A | Restricted Stock Units | 12,810 | 0.00 | — | 12,810 | D | ↗ |
| 2025-06-30 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 756 | 0.00 | — | 36,448 | D | ↗ |
| 2025-06-30 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 1,080 | 0.00 | — | 59,477 | D | ↗ |
| 2025-06-30 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 810 | 0.00 | — | 32,497 | D | ↗ |
| 2025-06-30 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 728 | 0.00 | — | 9,172 | D | ↗ |
| 2025-06-30 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 729 | 0.00 | — | 62,989 | D | ↗ |
| 2025-06-13 | BOERNER CHRISTOPHER S. | Director / Officer | G-Gift | A | Common Stock, $0.10 par value | 62,719 | 0.00 | — | 125,439 | I | ↗ |
| 2025-06-09 | Shibutani Hiroshi Chris | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-03 | Short Bartie Wendy | Officer | M-Exempt | D | Restricted Stock Units | 8,040 | 0.00 | — | 16,080 | D | ↗ |
| 2025-06-03 | BOERNER CHRISTOPHER S. | Director / Officer | G-Gift | D | Common Stock, $0.10 par value | 62,720 | 0.00 | — | 62,719 | D | ↗ |
| 2025-06-01 | Short Bartie Wendy | Officer | — | — | Restricted Stock Units | 8,612 | 0.00 | — | 0 | D | ↗ |
| 2025-05-09 | Hickey Benjamin | Officer | S-Sale | D | Common Stock, $0.10 par value | 97 | 38.01 | 3.7K | 0 | I | ↗ |
| 2025-05-01 | Lenkowsky Adam | Officer | J-Other | D | Market Share Units | 1,373 | 0.00 | — | 2,748 | D | ↗ |
| 2025-04-25 | Hirawat Samit | Officer | P-Purchase | A | Common Stock, $0.10 par value | 4,250 | 47.58 | 202.2K | 83,513 | D | ↗ |
| 2025-04-01 | Shanahan Karin | Officer | M-Exempt | A | Common Stock, $0.10 par value | 3,306 | 0.00 | — | 15,489 | D | ↗ |
| 2025-03-31 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 574 | 0.00 | — | 35,251 | D | ↗ |
| 2025-03-31 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 820 | 0.00 | — | 57,676 | D | ↗ |
| 2025-03-31 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 615 | 0.00 | — | 31,296 | D | ↗ |
| 2025-03-31 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 512 | 0.00 | — | 8,339 | D | ↗ |
| 2025-03-31 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 553 | 0.00 | — | 61,491 | D | ↗ |
| 2025-03-10 | Shanahan Karin | Officer | A-Award | A | Performance Shares | 30,126 | 0.00 | — | 30,126 | D | ↗ |
| 2025-03-10 | Poole Ahn Amanda | Officer | F-InKind | D | Common Stock, $0.10 par value | 233 | 63.11 | 14.7K | 2,833 | D | ↗ |
| 2025-03-10 | Plenge Robert M | Officer | J-Other | D | Common Stock, $0.10 par value | 193 | 0.00 | — | 12,832 | D | ↗ |
| 2025-03-10 | Meyers Gregory Scott | Officer | F-InKind | D | Common Stock, $0.10 par value | 1,159 | 63.11 | 73.1K | 9,916 | D | ↗ |
| 2025-03-10 | Lenkowsky Adam | Officer | F-InKind | D | Common Stock, $0.10 par value | 3,538 | 63.11 | 223.3K | 12,439 | D | ↗ |
| 2025-03-10 | LEUNG SANDRA | Officer | M-Exempt | A | Common Stock, $0.10 par value | 32,096 | 0.00 | — | 386,496 | D | ↗ |
| 2025-03-10 | Holzer Phil M | Officer | M-Exempt | D | Market Share Units | 810 | 0.00 | — | 811 | D | ↗ |
| 2025-03-10 | Hoch Lynelle | Officer | M-Exempt | D | Performance Shares | 5,015 | 0.00 | — | 0 | D | ↗ |
| 2025-03-10 | Hirawat Samit | Officer | J-Other | D | Common Stock, $0.10 par value | 10,545 | 0.00 | — | 88,495 | D | ↗ |
| 2025-03-10 | Hickey Benjamin | Officer | A-Award | A | Performance Shares | 20,084 | 0.00 | — | 20,084 | D | ↗ |
| 2025-03-10 | Gallman Cari | Officer | A-Award | A | Market Share Units | 13,389 | 0.00 | — | 13,389 | D | ↗ |
| 2025-03-10 | Elkins David V | Officer | A-Award | A | Performance Shares | 54,226 | 0.00 | — | 54,226 | D | ↗ |
| 2025-03-10 | BOERNER CHRISTOPHER S. | Director / Officer | M-Exempt | A | Common Stock, $0.10 par value | 39,700 | 0.00 | — | 152,898 | D | ↗ |
| 2025-03-01 | Hickey Benjamin | Officer | F-InKind | D | Common Stock, $0.10 par value | 1,630 | 59.62 | 97.2K | 8,789 | D | ↗ |
| 2025-02-20 | BOERNER CHRISTOPHER S. | Director / Officer | P-Purchase | A | Common Stock, $0.10 par value | 2,000 | 55.05 | 110.1K | 104,626 | D | ↗ |
| 2025-02-14 | Hirawat Samit | Officer | P-Purchase | A | Common Stock, $0.10 par value | 1,823 | 54.84 | 100.0K | 63,932 | D | ↗ |
| 2025-02-01 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 34,677 | D | ↗ |
| 2025-02-01 | Vousden Karen H | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 35,232 | D | ↗ |
| 2025-02-01 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 56,856 | D | ↗ |
| 2025-02-01 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 30,681 | D | ↗ |
| 2025-02-01 | Price Paula A | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 20,434 | D | ↗ |
| 2025-02-01 | Meyers Gregory Scott | Officer | M-Exempt | D | Restricted Stock Units | 2,543 | 0.00 | — | 2,543 | D | ↗ |
| 2025-02-01 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 7,827 | D | ↗ |
| 2025-02-01 | Hidalgo Medina Manuel | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 17,836 | D | ↗ |
| 2025-02-01 | Hickey Benjamin | Officer | F-InKind | D | Common Stock, $0.10 par value | 3,725 | 58.95 | 219.6K | 7,133 | D | ↗ |
| 2025-02-01 | Haller Julia A | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 32,223 | D | ↗ |
| 2025-02-01 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 14,488 | D | ↗ |
| 2025-02-01 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 3,562 | 0.00 | — | 60,938 | D | ↗ |
| 2024-12-31 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 619 | 0.00 | — | 30,796 | D | ↗ |
| 2024-12-31 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 884 | 0.00 | — | 52,749 | D | ↗ |
| 2024-12-31 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 663 | 0.00 | — | 26,841 | D | ↗ |
| 2024-12-31 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 553 | 0.00 | — | 4,221 | D | ↗ |
| 2024-12-31 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 597 | 0.00 | — | 56,788 | D | ↗ |
| 2024-11-04 | Holzer Phil M | Officer | S-Sale | D | Common Stock, $0.10 par value | 700 | 55.62 | 38.9K | 11,760 | D | ↗ |
| 2024-11-01 | Shanahan Karin | Officer | A-Award | A | Restricted Stock Units | 18,843 | 0.00 | — | 18,843 | D | ↗ |
| 2024-11-01 | Meyers Gregory Scott | Officer | A-Award | A | Restricted Stock Units | 18,843 | 0.00 | — | 18,843 | D | ↗ |
| 2024-11-01 | Hirawat Samit | Officer | P-Purchase | A | Common Stock, $0.10 par value | 1,830 | 54.68 | 100.1K | 62,109 | D | ↗ |
| 2024-11-01 | BOERNER CHRISTOPHER S. | Director / Officer | M-Exempt | A | Common Stock, $0.10 par value | 2,964 | 0.00 | — | 104,169 | D | ↗ |
| 2024-10-02 | Gallman Cari | Officer | F-InKind | D | Common Stock, $0.10 par value | 1,648 | 53.76 | 88.6K | 5,019 | D | ↗ |
| 2024-09-30 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 676 | 0.00 | — | 29,848 | D | ↗ |
| 2024-09-30 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 966 | 0.00 | — | 51,298 | D | ↗ |
| 2024-09-30 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 725 | 0.00 | — | 25,892 | D | ↗ |
| 2024-09-30 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 604 | 0.00 | — | 3,628 | D | ↗ |
| 2024-09-30 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 169 | 0.00 | — | 10,696 | D | ↗ |
| 2024-09-30 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 652 | 0.00 | — | 55,578 | D | ↗ |
| 2024-08-01 | Gallman Cari | Officer | M-Exempt | A | Common Stock, $0.10 par value | 1,061 | 0.00 | — | 2,493 | — | ↗ |
| 2024-07-29 | McMullen Michael R. | Director | J-Other | D | Call Option (obligation to sell) | 5 | 46.00 | 230.00 | 0 | — | ↗ |
| 2024-07-01 | McMullen Michael R. | Director | A-Award | A | Deferred Share Units | 2,987 | 0.00 | — | 2,987 | — | ↗ |
| 2024-06-30 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 843 | 0.00 | — | 28,813 | — | ↗ |
| 2024-06-30 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 1,204 | 0.00 | — | 49,712 | — | ↗ |
| 2024-06-30 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 903 | 0.00 | — | 24,858 | — | ↗ |
| 2024-06-30 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 211 | 0.00 | — | 10,397 | — | ↗ |
| 2024-06-30 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 826 | 0.00 | — | 54,250 | — | ↗ |
| 2024-06-24 | McMullen Michael R. | Director | — | I | Call Option (obligation to sell) | 500 | 46.00 | 23.0K | 0 | — | ↗ |
| 2024-05-01 | Lenkowsky Adam | Officer | J-Other | D | Market Share Units | 1,373 | 0.00 | — | 4,121 | — | ↗ |
| 2024-04-01 | Shanahan Karin | Officer | M-Exempt | A | Common Stock, $0.10 par value | 3,306 | 0.00 | — | 6,532 | — | ↗ |
| 2024-03-31 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 645 | 0.00 | — | 27,595 | — | ↗ |
| 2024-03-31 | Storch Gerald L | Director | A-Award | A | Deferred Share Units | 691 | 0.00 | — | 88,159 | — | ↗ |
| 2024-03-31 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 922 | 0.00 | — | 47,859 | — | ↗ |
| 2024-03-31 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 691 | 0.00 | — | 23,634 | — | ↗ |
| 2024-03-31 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 161 | 0.00 | — | 10,050 | — | ↗ |
| 2024-03-31 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 645 | 0.00 | — | 52,709 | — | ↗ |
| 2024-03-10 | Shanahan Karin | Officer | A-Award | A | Performance Shares | 34,830 | 0.00 | — | 34,830 | — | ↗ |
| 2024-03-10 | Poole Ahn Amanda | Officer | F-InKind | D | Common Stock, $0.10 par value | 207 | 53.79 | 11.1K | 701 | — | ↗ |
| 2024-03-10 | Plenge Robert M | Officer | A-Award | A | Performance Shares | 23,220 | 0.00 | — | 23,220 | — | ↗ |
| 2024-03-10 | Meyers Gregory Scott | Officer | A-Award | A | Performance Shares | 29,025 | 0.00 | — | 29,025 | — | ↗ |
| 2024-03-10 | Lenkowsky Adam | Officer | A-Award | A | Performance Shares | 31,347 | 0.00 | — | 31,347 | — | ↗ |
| 2024-03-10 | LEUNG SANDRA | Officer | J-Other | D | Common Stock, $0.10 par value | 912 | 0.00 | — | 336,291 | — | ↗ |
| 2024-03-10 | Holzer Phil M | Officer | J-Other | D | Market Share Units | 768 | 0.00 | — | 2,307 | — | ↗ |
| 2024-03-10 | Hoch Lynelle | Officer | J-Other | D | Market Share Units | 835 | 0.00 | — | 1,673 | — | ↗ |
| 2024-03-10 | Hirawat Samit | Officer | M-Exempt | D | Performance Shares | 29,311 | 0.00 | — | 0 | — | ↗ |
| 2024-03-10 | Hickey Benjamin | Officer | A-Award | A | Performance Shares | 5,805 | 0.00 | — | 5,805 | — | ↗ |
| 2024-03-10 | Gallman Cari | Officer | F-InKind | D | Common Stock, $0.10 par value | 105 | 53.79 | 5.6K | 561 | — | ↗ |
| 2024-03-10 | Elkins David V | Officer | M-Exempt | A | Common Stock, $0.10 par value | 8,042 | 0.00 | — | 181,064 | — | ↗ |
| 2024-03-10 | Caforio Giovanni | Director / Officer | M-Exempt | D | Performance Shares | 142,904 | 0.00 | — | 0 | — | ↗ |
| 2024-03-10 | BOERNER CHRISTOPHER S. | Director / Officer | A-Award | A | Performance Shares | 148,026 | 0.00 | — | 148,026 | — | ↗ |
| 2024-03-01 | Hickey Benjamin | Officer | A-Award | A | Restricted Stock Units | 9,858 | 0.00 | — | 9,858 | — | ↗ |
| 2024-02-26 | Hickey Benjamin | Officer | — | D | Common Stock, $0.10 par value | 0 | 0.00 | — | 780 | — | ↗ |
| 2024-02-15 | Holzer Phil M | Officer | — | D | Market Share Units | 3,075 | 0.00 | — | 0 | — | ↗ |
| 2024-02-01 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 26,950 | — | ↗ |
| 2024-02-01 | Vousden Karen H | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 30,212 | — | ↗ |
| 2024-02-01 | Storch Gerald L | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 87,467 | — | ↗ |
| 2024-02-01 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 46,937 | — | ↗ |
| 2024-02-01 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 22,943 | — | ↗ |
| 2024-02-01 | Price Paula A | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 16,095 | — | ↗ |
| 2024-02-01 | Meyers Gregory Scott | Officer | M-Exempt | D | Restricted Stock Units | 2,543 | 0.00 | — | 5,086 | — | ↗ |
| 2024-02-01 | Hidalgo Medina Manuel | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 13,616 | — | ↗ |
| 2024-02-01 | Haller Julia A | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 27,341 | — | ↗ |
| 2024-02-01 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 9,889 | — | ↗ |
| 2024-02-01 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 4,315 | 0.00 | — | 52,063 | — | ↗ |
| 2024-01-01 | Poole Ahn Amanda | Officer | — | D | Market Share Units | 3,214 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 658 | 0.00 | — | 22,359 | — | ↗ |
| 2023-12-31 | Storch Gerald L | Director | A-Award | A | Deferred Share Units | 706 | 0.00 | — | 82,140 | — | ↗ |
| 2023-12-31 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 950 | 0.00 | — | 42,103 | — | ↗ |
| 2023-12-31 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 706 | 0.00 | — | 18,401 | — | ↗ |
| 2023-12-31 | Hidalgo Medina Manuel | Director | A-Award | A | Deferred Share Units | 164 | 0.00 | — | 9,188 | — | ↗ |
| 2023-12-31 | Haller Julia A | Director | A-Award | A | Deferred Share Units | 706 | 0.00 | — | 22,746 | — | ↗ |
| 2023-12-31 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 164 | 0.00 | — | 5,506 | — | ↗ |
| 2023-12-31 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 658 | 0.00 | — | 47,167 | — | ↗ |
| 2023-12-15 | Hoch Lynelle | Officer | — | D | Performance Shares | 6,304 | 0.00 | — | 0 | — | ↗ |
| 2023-12-05 | BOERNER CHRISTOPHER S. | Officer | P-Purchase | A | Common Stock, $0.10 par value | 2,000 | 49.78 | 99.6K | 82,672 | — | ↗ |
| 2023-12-02 | Plenge Robert M | Officer | F-InKind | D | Common Stock, $0.10 par value | 274 | 50.10 | 13.7K | 6,926 | — | ↗ |
| 2023-12-02 | Elkins David V | Officer | M-Exempt | A | Common Stock, $0.10 par value | 8,792 | 0.00 | — | 172,342 | — | ↗ |
| 2023-12-02 | BOERNER CHRISTOPHER S. | Officer | M-Exempt | A | Common Stock, $0.10 par value | 2,638 | 0.00 | — | 82,022 | — | ↗ |
| 2023-11-28 | BOERNER CHRISTOPHER S. | Officer | P-Purchase | A | Common Stock, $0.10 par value | 3,071 | 48.86 | 150.0K | 79,384 | — | ↗ |
| 2023-11-21 | LEUNG SANDRA | Officer | J-Other | D | Common Stock, $0.10 par value | 9,830 | 48.75 | 479.2K | 331,414 | — | ↗ |
| 2023-11-20 | Samuels Theodore R. II | Director | P-Purchase | A | Common Stock, $0.10 par value | 8,500 | 49.81 | 423.4K | 35,500 | — | ↗ |
| 2023-11-01 | BOERNER CHRISTOPHER S. | Officer | A-Award | A | Performance Shares | 17,788 | 0.00 | — | 17,788 | — | ↗ |
| 2023-10-10 | Caforio Giovanni | Director / Officer | G-Gift | D | Common Stock, $0.10 par value | 440 | 0.00 | — | 367,495 | — | ↗ |
| 2023-10-02 | Gallman Cari | Officer | A-Award | A | Restricted Stock Units | 13,675 | 0.00 | — | 13,675 | — | ↗ |
| 2023-09-30 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 581 | 0.00 | — | 21,463 | — | ↗ |
| 2023-09-30 | Storch Gerald L | Director | A-Award | A | Deferred Share Units | 625 | 0.00 | — | 80,538 | — | ↗ |
| 2023-09-30 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 840 | 0.00 | — | 40,701 | — | ↗ |
| 2023-09-30 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 625 | 0.00 | — | 17,500 | — | ↗ |
| 2023-09-30 | Haller Julia A | Director | A-Award | A | Deferred Share Units | 625 | 0.00 | — | 21,797 | — | ↗ |
| 2023-09-30 | Bhatt Deepak | Director | A-Award | A | Deferred Share Units | 145 | 0.00 | — | 5,283 | — | ↗ |
| 2023-09-30 | Arduini Peter J | Director | A-Award | A | Deferred Share Units | 581 | 0.00 | — | 45,998 | — | ↗ |
| 2023-08-24 | Powell Ann | Officer | S-Sale | D | Common Stock, $0.10 par value | 17,986 | 61.25 | 1.10M | 27,868 | — | ↗ |
| 2023-08-03 | Plenge Robert M | Officer | S-Sale | D | Common Stock, $0.10 par value | 732 | 61.14 | 44.8K | 6,584 | — | ↗ |
| 2023-07-03 | Plenge Robert M | Officer | — | D | Restricted Stock Units | 616 | 0.00 | — | 0 | — | ↗ |
| 2023-07-01 | Weese Michelle | Officer | F-InKind | D | Common Stock, $0.10 par value | 682 | 63.95 | 43.6K | 3,453 | — | ↗ |
| 2023-07-01 | Hirawat Samit | Officer | M-Exempt | D | Restricted Stock Units | 9,357 | 0.00 | — | 0 | — | ↗ |
| 2023-06-30 | YALE PHYLLIS R | Director | A-Award | A | Deferred Share Units | 528 | 0.00 | — | 20,690 | — | ↗ |
| 2023-06-30 | Storch Gerald L | Director | A-Award | A | Deferred Share Units | 567 | 0.00 | — | 79,180 | — | ↗ |
| 2023-06-30 | Samuels Theodore R. II | Director | A-Award | A | Deferred Share Units | 762 | 0.00 | — | 39,495 | — | ↗ |
| 2023-06-30 | Rice Derica W | Director | A-Award | A | Deferred Share Units | 567 | 0.00 | — | 16,721 | — | ↗ |
| 2023-06-30 | Haller Julia A | Director | A-Award | A | Deferred Share Units | 554 | 0.00 | — | 20,978 | — | ↗ |
Executive team
Top executives
EBIT / Employee
313.3K
Shares Outstanding
2.04B
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Christopher S. Boerner, Ph.D. Board Chair and Chief Executive Officer | 1.59M | — | 16.06M | — | 3.75M | 477.5K | 21.88M | 73.41% | ↗ |
| 2 | 2025 | Samit Hirawat , M.D. Former EVP, Chief Medical Officer, Head of Development | 964.9K | — | 5.82M | — | 928.7K | 2.63M | 10.33M | 56.27% | ↗ |
| 3 | 2025 | Cristian Massacesi , M.D. EVP, Chief Medical Officer, Head of Development | 388.5K | 1.13M | 7.85M | — | 660.9K | 44.6K | 10.07M | 77.97% | ↗ |
| 4 | 2025 | Adam Lenkowsky EVP, Chief Commercialization Officer | 1.13M | — | 6.14M | — | 1.79M | 277.1K | 9.34M | 65.70% | ↗ |
| 5 | 2025 | David V. Elkins EVP and Chief Financial Officer | 1.14M | — | 5.98M | — | 1.80M | 256.2K | 9.18M | 65.18% | ↗ |
| 6 | 2025 | Greg Meyers EVP, Chief Digital and Technology Officer | 1.07M | — | 4.21M | — | 1.67M | 230.3K | 7.18M | 58.61% | ↗ |
| 7 | 2024 | Christopher S. Boerner, Ph.D. Board Chair and Chief Executive Officer | 1.54M | — | 13.64M | — | 3.24M | 372.4K | 18.79M | 72.62% | ↗ |
| 8 | 2024 | David V. Elkins EVP and Chief Financial Officer | 1.12M | — | 5.78M | — | 1.56M | 250.1K | 8.71M | 66.36% | ↗ |
| 9 | 2024 | Samit Hirawat , M.D. Former EVP, Chief Medical Officer, Head of Development | 1.12M | — | 5.62M | — | 1.56M | 289.0K | 8.59M | 65.43% | ↗ |
| 10 | 2024 | Samit Hirawat, M.D. EVP, Chief Medical Officer, Head of Development | 1.12M | — | 5.62M | — | 1.56M | 289.0K | 8.59M | 65.43% | ↗ |
| 11 | 2024 | Sandra Leung EVP and General Counsel | 1.15M | — | 3.96M | — | 1.61M | 289.3K | 7.01M | 56.46% | ↗ |
| 12 | 2024 | Karin Shanahan EVP, Global Product Development & Supply | 1.01M | — | 4.15M | — | 1.28M | 132.4K | 6.57M | 63.14% | ↗ |
| 13 | 2023 | Giovanni Caforio, M.D. Executive Chair and Former Chief Executive Officer | 1.75M | — | 14.47M | — | 2.71M | 734.6K | 19.66M | 73.57% | ↗ |
| 14 | 2023 | Christopher S. Boerner, Ph.D. Chief Executive Officer | 1.26M | — | 5.33M | — | 1.57M | 311.6K | 8.46M | 62.94% | ↗ |
| 15 | 2023 | Christopher S. Boerner, Ph.D. Board Chair and Chief Executive Officer | 1.26M | — | 5.33M | — | 1.57M | 311.6K | 8.46M | 62.94% | ↗ |
| 16 | 2023 | David V. Elkins EVP and Chief Financial Officer | 1.11M | — | 4.88M | — | 866.3K | 311.7K | 7.17M | 68.13% | ↗ |
| 17 | 2023 | Samit Hirawat, M.D. EVP, Chief Medical Officer, Head of Development | 1.10M | — | 3.62M | — | 1.23M | 279.3K | 6.23M | 58.01% | ↗ |
| 18 | 2023 | Samit Hirawat , M.D. Former EVP, Chief Medical Officer, Head of Development | 1.10M | — | 3.62M | — | 1.23M | 279.3K | 6.23M | 58.01% | ↗ |
| 19 | 2023 | Sandra Leung EVP and General Counsel | 1.15M | — | 3.35M | — | 1.12M | 307.4K | 5.92M | 56.47% | ↗ |
| 20 | 2023 | Elizabeth Mily EVP, Strategy & Business Development | 992.1K | — | 2.26M | — | 895.0K | 200.8K | 4.35M | 51.98% | ↗ |
| 21 | 2022 | Giovanni Caforio, M.D. Executive Chair and Former Chief Executive Officer | 1.70M | — | 14.29M | — | 3.45M | 613.3K | 20.05M | 71.26% | ↗ |
| 22 | 2022 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1.70M | — | 14.29M | — | 3.45M | 613.3K | 20.05M | 71.26% | ↗ |
| 23 | 2022 | David V. Elkins EVP and Chief Financial Officer | 1.07M | — | 4.92M | — | 1.40M | 253.0K | 7.65M | 64.37% | ↗ |
| 24 | 2022 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP and President, Research | 1.08M | — | 4.60M | — | 1.41M | 260.3K | 7.35M | 62.52% | ↗ |
| 25 | 2022 | Christopher S. Boerner, Ph.D. Board Chair and Chief Executive Officer | 1.06M | — | 4.26M | — | 1.27M | 285.3K | 6.88M | 61.86% | ↗ |
| 26 | 2022 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 1.06M | — | 4.26M | — | 1.27M | 285.3K | 6.88M | 61.86% | ↗ |
| 27 | 2022 | Christopher S. Boerner, Ph.D. Chief Executive Officer | 1.06M | — | 4.26M | — | 1.27M | 285.3K | 6.88M | 61.86% | ↗ |
| 28 | 2022 | Sandra Leung EVP and General Counsel | 1.13M | — | 3.44M | — | 1.24M | 291.7K | 6.10M | 56.37% | ↗ |
| 29 | 2021 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1.70M | — | 13.97M | — | 3.41M | 708.2K | 19.78M | 70.59% | ↗ |
| 30 | 2021 | Giovanni Caforio, M.D. Executive Chair and Former Chief Executive Officer | 1.70M | — | 13.97M | — | 3.41M | 708.2K | 19.78M | 70.59% | ↗ |
| 31 | 2021 | David V. Elkins EVP and Chief Financial Officer | 1.03M | 525.0K | 4.72M | — | 1.34M | 284.7K | 7.90M | 59.74% | ↗ |
| 32 | 2021 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1.04M | 500.0K | 4.59M | — | 1.36M | 321.6K | 7.80M | 58.81% | ↗ |
| 33 | 2021 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP and President, Research | 1.04M | 500.0K | 4.59M | — | 1.36M | 321.6K | 7.80M | 58.81% | ↗ |
| 34 | 2021 | Christopher S. Boerner, Ph.D. Chief Executive Officer | 1.02M | — | 4.10M | — | 1.31M | 273.2K | 6.70M | 61.10% | ↗ |
| 35 | 2021 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 1.02M | — | 4.10M | — | 1.31M | 273.2K | 6.70M | 61.10% | ↗ |
| 36 | 2021 | Sandra Leung EVP and General Counsel | 1.10M | — | 3.43M | — | 1.30M | 329.1K | 6.16M | 55.73% | ↗ |
| 37 | 2020 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1.69M | — | 13.46M | — | 4.20M | 804.9K | 20.15M | 66.78% | ↗ |
| 38 | 2020 | David V. Elkins EVP and Chief Financial Officer | 1.02M | 525.0K | 4.41M | — | 1.68M | 17.1K | 7.65M | 57.63% | ↗ |
| 39 | 2020 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1.02M | 500.0K | 4.08M | — | 1.70M | 17.1K | 7.32M | 55.76% | ↗ |
| 40 | 2020 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP and President, Research | 1.02M | 500.0K | 4.08M | — | 1.70M | 17.1K | 7.32M | 55.76% | ↗ |
| 41 | 2020 | Sandra Leung EVP and General Counsel | 1.07M | — | 3.33M | — | 1.64M | 1.20M | 7.24M | 45.98% | ↗ |
| 42 | 2020 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 952.6K | — | 3.21M | — | 1.58M | 247.0K | 5.99M | 53.58% | ↗ |
| 43 | 2019 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1.65M | — | 12.55M | — | 3.89M | 686.0K | 18.77M | 66.85% | ↗ |
| 44 | 2019 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1.65M | — | 12.55M | — | 3.89M | 686.0K | 18.77M | 66.85% | ↗ |
| 45 | 2019 | Charles Bancroft EVP, Head of Integration and Strategy & Business Development Former CFO and EVP, Head of Global Business Operations | 1.06M | — | 4.16M | — | 1.99M | 2.32M | 9.53M | 43.62% | ↗ |
| 46 | 2019 | Thomas J. Lynch, Jr., M.D. Former EVP and Chief Scientific Officer | 796.1K | — | 3.78M | — | 1.22M | 2.49M | 8.29M | 45.65% | ↗ |
| 47 | 2019 | Sandra Leung EVP and General Counsel | 1.01M | — | 3.17M | — | 1.59M | 1.75M | 7.52M | 42.21% | ↗ |
| 48 | 2019 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 891.3K | — | 3.25M | — | 1.40M | 199.6K | 5.74M | 56.62% | ↗ |
| 49 | 2019 | David V. Elkins EVP and Chief Financial Officer | 116.7K | 1.05M | 1.87M | — | 1.32M | 15.5K | 4.37M | 42.68% | ↗ |
| 50 | 2019 | David Elkins EVP and Chief Financial Officer | 116.7K | 1.05M | 1.87M | — | 1.32M | 15.5K | 4.37M | 42.68% | ↗ |
| 51 | 2019 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP and President, Research and Early Development | 116.7K | 1.00M | 1.87M | — | 1.24M | 11.6K | 4.24M | 44.05% | ↗ |
| 52 | 2019 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 116.7K | 1.00M | 1.87M | — | 1.24M | 11.6K | 4.24M | 44.05% | ↗ |
| 53 | 2018 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1.64M | — | 13.01M | — | 4.07M | 664.4K | 19.38M | 67.14% | ↗ |
| 54 | 2018 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1.64M | — | 13.01M | — | 4.07M | 664.4K | 19.38M | 67.14% | ↗ |
| 55 | 2018 | Charles Bancroft EVP, Head of Integration and Strategy & Business Development Former CFO and EVP, Head of Global Business Operations | 1.03M | — | 4.31M | — | 2.20M | 349.7K | 7.89M | 54.64% | ↗ |
| 56 | 2018 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 1.03M | — | 4.31M | — | 2.20M | 349.7K | 7.89M | 54.64% | ↗ |
| 57 | 2018 | Thomas J. Lynch, Jr., M.D. Former EVP and Chief Scientific Officer | 1.02M | — | 4.08M | — | 1.63M | 311.4K | 7.03M | 57.93% | ↗ |
| 58 | 2018 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 1.02M | — | 4.08M | — | 1.63M | 311.4K | 7.03M | 57.93% | ↗ |
| 59 | 2018 | Sandra Leung EVP and General Counsel | 975.9K | — | 3.29M | — | 1.68M | 296.4K | 6.24M | 52.71% | ↗ |
| 60 | 2018 | Louis Schmukler SVP and President, Global Product Development and Supply | 804.6K | — | 2.05M | — | 1.07M | 209.4K | 4.13M | 49.61% | ↗ |
| 61 | 2017 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1.59M | — | 12.65M | — | 3.90M | 550.0K | 18.69M | 67.70% | ↗ |
| 62 | 2017 | Charles Bancroft EVP, Head of Integration and Strategy & Business Development Former CFO and EVP, Head of Global Business Operations | 997.3K | — | 4.32M | — | 1.89M | 1.61M | 8.82M | 49.01% | ↗ |
| 63 | 2017 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 997.3K | — | 4.32M | — | 1.89M | 1.61M | 8.82M | 49.01% | ↗ |
| 64 | 2017 | Thomas J. Lynch, Jr., M.D. Former EVP and Chief Scientific Officer | 796.2K | 1.40M | 4.43M | — | 1.58M | 113.5K | 8.31M | 53.24% | ↗ |
| 65 | 2017 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 796.2K | 1.40M | 4.43M | — | 1.58M | 113.5K | 8.31M | 53.24% | ↗ |
| 66 | 2017 | Sandra Leung EVP and General Counsel | 947.4K | — | 3.05M | — | 1.49M | 1.05M | 6.54M | 46.58% | ↗ |
| 67 | 2017 | Murdo Gordon EVP and Chief Commercial Officer | 845.0K | — | 2.79M | — | 1.18M | 578.1K | 5.39M | 51.68% | ↗ |
| 68 | 2016 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1.51M | — | 11.82M | — | 3.00M | 601.1K | 16.93M | 69.82% | ↗ |
| 69 | 2016 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 966.1K | — | 4.01M | — | 1.53M | 351.4K | 6.97M | 57.56% | ↗ |
| 70 | 2013 | Lamberto Andreotti Chief Executive Officer | 1.69M | — | 14.59M | — | 3.80M | 774.4K | 20.85M | 69.97% | ↗ |
| 71 | 2013 | Charles Bancroft EVP and Chief Financial Officer | 901.1K | — | 4.78M | — | 1.13M | 311.2K | 7.88M | 60.65% | ↗ |
| 72 | 2013 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 564.5K | — | 5.89M | — | 653.1K | 340.8K | 7.45M | 79.08% | ↗ |
| 73 | 2013 | Beatrice Cazala Former EVP, Commercial Operations | 894.7K | — | 3.61M | — | 895.9K | 75.6K | 5.48M | 65.93% | ↗ |
| 74 | 2013 | Sandra Leung General Counsel Corporate Secretary | 843.1K | — | 2.88M | — | 844.2K | 245.0K | 4.82M | 59.88% | ↗ |
| 75 | 2013 | Francis Cuss, MB, | 736.1K | — | 2.02M | — | 748.4K | 153.0K | 3.72M | 54.21% | ↗ |
| 76 | 2013 | Giovanni Caforio, M.D. Chief Operating Officer | 748.3K | — | 1.59M | — | 788.6K | 177.9K | 3.30M | 48.07% | ↗ |
| 77 | 2012 | Lamberto Andreotti Chief Executive Officer | 1.62M | — | 9.72M | — | 3.84M | 818.1K | 17.20M | 56.52% | ↗ |
| 78 | 2012 | Charles Bancroft EVP and Chief Financial Officer | 868.6K | — | 2.40M | — | 1.32M | 318.6K | 8.57M | 27.96% | ↗ |
| 79 | 2012 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1.06M | — | 3.22M | — | 1.87M | 450.1K | 8.34M | 38.59% | ↗ |
| 80 | 2012 | Beatrice Cazala Former EVP, Commercial Operations | 868.6K | — | 2.45M | — | 1.13M | 68.4K | 8.03M | 30.45% | ↗ |
| 81 | 2012 | Sandra Leung General Counsel Corporate Secretary | 768.7K | — | 2.02M | — | 907.3K | 243.2K | 5.89M | 34.29% | ↗ |
| 82 | 2011 | Lamberto Andreotti Chief Executive Officer | 1.51M | — | 7.35M | — | 4.22M | 649.8K | 14.91M | 49.30% | ↗ |
| 83 | 2011 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1.03M | — | 2.91M | — | 2.15M | 418.3K | 9.03M | 32.20% | ↗ |
| 84 | 2011 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1.03M | — | 2.91M | — | 2.15M | 418.3K | 9.03M | 32.20% | ↗ |
| 85 | 2011 | Charles A. Bancroft EVP and Chief Financial Officer | 809.7K | — | 2.15M | — | 1.41M | 250.4K | 7.37M | 29.18% | ↗ |
| 86 | 2011 | Charles Bancroft EVP and Chief Financial Officer | 809.7K | — | 2.15M | — | 1.41M | 250.4K | 7.37M | 29.18% | ↗ |
| 87 | 2011 | Beatrice Cazala Former EVP, Commercial Operations | 895.1K | — | 2.60M | — | 1.35M | 132.6K | 5.94M | 43.80% | ↗ |
| 88 | 2011 | Beatrice Cazala Former EVP, Commercial Operations | 895.1K | — | 2.60M | — | 1.35M | 132.6K | 5.94M | 43.80% | ↗ |
| 89 | 2011 | Anthony C. Hooper SVP Commercial Operations President US, Japan and Intercontinental | 711.3K | — | 2.31M | — | 867.2K | 273.4K | 5.89M | 39.18% | ↗ |
| 90 | 2011 | Sandra Leung General Counsel | 724.6K | — | 1.83M | — | 968.1K | 213.1K | 5.49M | 33.27% | ↗ |
| 91 | 2011 | Sandra Leung General Counsel Corporate Secretary | 724.6K | — | 1.83M | — | 968.1K | 213.1K | 5.49M | 33.27% | ↗ |
| 92 | 2010 | Lamberto Andreotti Chief Executive Officer | 1.35M | — | 5.81M | — | 3.13M | 619.4K | 11.77M | 49.35% | ↗ |
| 93 | 2010 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1.02M | — | 2.92M | — | 1.95M | 449.4K | 8.28M | 35.24% | ↗ |
| 94 | 2010 | Sandra Leung General Counsel | 675.0K | — | 1.82M | — | 797.6K | 223.0K | 4.63M | 39.40% | ↗ |
| 95 | 2010 | Charles A. Bancroft EVP and Chief Financial Officer | 678.8K | — | 1.00M | — | 978.6K | 142.4K | 4.22M | 23.71% | ↗ |
| 96 | 2009 | James M. Cornelius Chairman Chief Executive Officer | 1.50M | — | 5.66M | 5.21M | 4.49M | 136.4K | 18.22M | 59.66% | ↗ |
| 97 | 2009 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO President RD | 1.01M | — | 3.44M | 1.35M | 2.19M | 45.7K | 10.00M | 47.85% | ↗ |
| 98 | 2009 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1.01M | — | 3.44M | 1.35M | 2.19M | 45.7K | 10.00M | 47.85% | ↗ |
| 99 | 2009 | Lamberto Andreotti President Chief Operating Officer | 1.24M | — | 1.64M | 1.68M | 3.08M | 56.0K | 9.01M | 36.88% | ↗ |
| 100 | 2009 | Anthony C. Hooper President, Americas | 782.3K | — | 1.01M | 1.02M | 1.11M | 35.2K | 5.03M | 40.34% | ↗ |
| 101 | 2009 | Jean-Marc Huet Former EVP CFO | 913.4K | — | 1.19M | 1.35M | — | 42.9K | 3.75M | 67.82% | ↗ |
| 102 | 2008 | James M. Cornelius Chairman Chief Executive Officer | 1.49M | — | 5.12M | 7.15M | 4.48M | 136.3K | 19.71M | 62.25% | ↗ |
| 103 | 2008 | Lamberto Andreotti President Chief Operating Officer | 1.21M | — | 1.34M | 1.81M | 2.68M | 57.8K | 7.99M | 39.48% | ↗ |
| 104 | 2008 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO President RD | 985.8K | — | 1.34M | 1.81M | 2.08M | 49.4K | 7.85M | 40.16% | ↗ |
| 105 | 2008 | Jean-Marc Huet Former EVP CFO | 675.0K | 100.0K | 924.6K | 1.39M | 1.58M | 285.7K | 5.13M | 45.13% | ↗ |
| 106 | 2008 | Anthony C. Hooper President, Americas | 693.5K | — | 805.3K | 1.02M | 1.07M | 32.6K | 4.41M | 41.28% | ↗ |
| 107 | 2007 | James M. Cornelius Chairman Chief Executive Officer | 1.35M | 1.06M | 3.15M | 3.35M | 2.22M | 425.0K | 12.48M | 52.11% | ↗ |
| 108 | 2007 | Lamberto Andreotti President Chief Operating Officer | 1.10M | — | 881.9K | 1.66M | 1.87M | 111.9K | 6.17M | 41.17% | ↗ |
| 109 | 2007 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO President RD | 880.3K | — | 904.2K | 1.73M | 1.43M | 112.8K | 6.13M | 42.90% | ↗ |
| 110 | 2007 | Anthony C. Hooper President, Americas | 643.9K | — | 885.8K | 738.6K | 681.7K | 49.4K | 3.50M | 46.38% | ↗ |
| 111 | 2006 | Peter R. Dolan Former Chief Executive Officer | 1.04M | — | — | 4.87M | — | 1.44M | 9.80M | 49.75% | ↗ |
| 112 | 2006 | Lamberto Andreotti EVP President WW Pharmaceuticals | 1.01M | — | 1.27M | 686.8K | 1.10M | 269.3K | 4.65M | 42.20% | ↗ |
| 113 | 2006 | Elliott Sigal, M.D., Ph.D. EVP, Chief Scientific Officer President PRI | 728.7K | — | 1.08M | 586.0K | 734.6K | 68.4K | 3.75M | 44.45% | ↗ |
| 114 | 2006 | Andrew R. J. Bonfield EVP Chief Financial Officer | 809.4K | — | 936.1K | 674.1K | 740.5K | 111.5K | 3.44M | 46.81% | ↗ |
| 115 | 2006 | Anthony C. Hooper President U.S. Pharmaceuticals | 618.0K | — | 569.7K | 377.2K | 465.0K | 44.8K | 2.42M | 39.06% | ↗ |
| 116 | 2006 | Stephen E. Bear SVP Human Resources | 466.1K | — | 512.9K | 369.3K | 292.5K | 38.0K | 2.15M | 41.07% | ↗ |
| 117 | 2006 | James M. Cornelius Interim Chief Executive Officer | 379.8K | — | — | 610.2K | — | 318.2K | 1.47M | 41.43% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer & Chairman | 6M | — |
| David V. Elkins | Executive Vice President & Chief Financial Officer | 3M | male |
| Adam Lenkowsky | Executive Vice President & Chief Commercialization Officer | 3M | male |
| Greg Meyers | Executive Vice President and Chief Digital & Technology Officer | 3M | male |
| Karin Shanahan | Executive Vice President, Chief Supply Chain & Operations Officer | 2M | female |
| Cristian Massacesi | Executive Vice President, Chief Medical Officer & Head of Development | 2M | male |
| Charles E. Triano | SVP & Head of Investor Relations | — | male |
| Cari Gallman | Executive Vice President, General Counsel & Chief Policy Officer | — | female |
| Joseph J. Eiden Jr. | Head of Medical Affairs | — | — |
| Ahn Amanda Poole | Executive Vice President & Chief People Officer | — | female |
| Wendy Short Bartie | Executive Vice President of Corporate Affairs | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - GENERAL
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-04-15 | 2025-05-15 | Tommy Tuberville | AL | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-04-15 | 2025-05-15 | Tommy Tuberville | AL | Self | Sale | $1,001 - $15,000 | ↗ |
| 2024-04-03 | 2024-05-15 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-04-03 | 2024-05-15 | Tommy Tuberville | AL | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2024-01-03 | 2024-02-14 | Tommy Tuberville | AL | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2023-11-16 | 2023-12-15 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-10-17 | 2023-11-16 | Tommy Tuberville | AL | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-08-22 | 2023-09-22 | Dan Sullivan | AK | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-05-10 | 2023-06-14 | Shelley Moore Capito | WV | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-01-10 | 2023-02-13 | Dan Sullivan | AK | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2022-06-17 | 2022-07-15 | Shelley Moore Capito | WV | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2022-01-18 | 2022-02-03 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2021-11-29 | 2021-12-04 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2020-12-30 | 2021-01-07 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2020-04-16 | 2021-05-02 | David Perdue | — | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-04-14 | 2020-05-01 | Kelly Loeffler | GA | Spouse | Sale (Full) | $250,001 - $500,000 | ↗ |
| 2020-04-14 | 2020-05-01 | Kelly Loeffler | GA | Self | Sale (Full) | $100,001 - $250,000 | ↗ |
| 2020-04-14 | 2021-05-02 | David Perdue | — | Joint | Sale (Partial) | $15,001 - $50,000 | ↗ |
| 2020-04-14 | 2021-05-02 | David Perdue | — | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2019-08-15 | 2019-09-03 | David Perdue | — | Joint | Sale (Partial) | $15,001 - $50,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | 2026-01-12 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-12-18 | 2026-01-16 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-11-13 | 2025-12-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-11-12 | 2025-12-15 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-09 | 2025-11-18 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-09-29 | 2025-10-03 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-09-05 | 2025-10-03 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-14 | 2025-09-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-06-24 | 2025-07-04 | Virginia Foxx | NC05 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-05-12 | 2025-06-23 | Jefferson Shreve | IN06 | — | Sale | $15,001 - $50,000 | ↗ |
| 2025-04-28 | 2026-01-13 | Julia Letlow | LA05 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-04-01 | 2025-05-15 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-03-27 | 2025-04-09 | Greg Landsman | OH01 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-01-15 | 2025-02-12 | Julie Johnson | TX32 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2024-12-06 | 2025-01-06 | Virginia Foxx | NC05 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-10-29 | 2025-09-12 | Valerie Hoyle | OR04 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2024-10-23 | 2026-01-13 | Julia Letlow | LA05 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-03-25 | 2024-04-05 | Ro Khanna | CA17 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2024-02-13 | 2024-03-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2024-02-13 | 2024-03-06 | Ro Khanna | CA17 | Spouse | Purchase | $15,001 - $50,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BMY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
